Nome dell'autore in nota nell'articolo. Abstract: BACKGROUND: The recent randomized, controlled trial of interferon-beta1b (IFN-beta1b) in 718 patients with secondary progressive MS (SP-MS) demonstrated a significant effect on the development of disability as evaluated by the physician. Its effect on patient-reported health-related quality of life (HrQoL) is reported herein. METHODS: In this multicenter, double-blind, randomized, placebo-controlled trial, outpatients with SP-MS scoring between 3.0 and 6.5 on the Expanded Disability Status Scale received either 8 x 10(6) IU of IFN-beta1b or placebo for up to 3 years. A range of outcomes was measured, including HrQoL, which was assessed using the Sickness Impact Profile (SIP), a self-report questionnaire validated for use in MS. Measurements were undertaken at baseline and at 6-monthly intervals thereafter for 36 months. RESULTS: A slight positive effect on the HrQoL of the IFN group in comparison with the placebo group was found, which reached significance in the physical scale of the SIP at 6 and 12 months and at last visit. There was moderate correlation between physician-assessed evaluation of change and patient-reported change. CONCLUSIONS: IFN-beta1b may delay sustained deterioration in patient-reported HrQoL in SP-MS. Methods of interpreting change in HrQoL are currently insufficiently developed to determine how clinically important these changes are for this population.

IFNbeta-1b in the treatment of secondary progressive Multiple Sclerosis: impact on quality of life / FREEMAN JA; THOMPSON AJ; FITZPATRICK R; HUTCHINSON M; MILTENBURGER C; BECKMANN K; DAHLKE F; KAPPOS L; POLMAN C; POZZILLI C; THE EUROPEAN STUDY GROUP ON INTERFERON BETA-1B IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS; MASSACESI L;. - In: NEUROLOGY. - ISSN 0028-3878. - ELETTRONICO. - 57:(2001), pp. 1870-1875. [10.1212/WNL.57.10.1870]

IFNbeta-1b in the treatment of secondary progressive Multiple Sclerosis: impact on quality of life.

MASSACESI, LUCA
2001

Abstract

Nome dell'autore in nota nell'articolo. Abstract: BACKGROUND: The recent randomized, controlled trial of interferon-beta1b (IFN-beta1b) in 718 patients with secondary progressive MS (SP-MS) demonstrated a significant effect on the development of disability as evaluated by the physician. Its effect on patient-reported health-related quality of life (HrQoL) is reported herein. METHODS: In this multicenter, double-blind, randomized, placebo-controlled trial, outpatients with SP-MS scoring between 3.0 and 6.5 on the Expanded Disability Status Scale received either 8 x 10(6) IU of IFN-beta1b or placebo for up to 3 years. A range of outcomes was measured, including HrQoL, which was assessed using the Sickness Impact Profile (SIP), a self-report questionnaire validated for use in MS. Measurements were undertaken at baseline and at 6-monthly intervals thereafter for 36 months. RESULTS: A slight positive effect on the HrQoL of the IFN group in comparison with the placebo group was found, which reached significance in the physical scale of the SIP at 6 and 12 months and at last visit. There was moderate correlation between physician-assessed evaluation of change and patient-reported change. CONCLUSIONS: IFN-beta1b may delay sustained deterioration in patient-reported HrQoL in SP-MS. Methods of interpreting change in HrQoL are currently insufficiently developed to determine how clinically important these changes are for this population.
2001
57
1870
1875
FREEMAN JA; THOMPSON AJ; FITZPATRICK R; HUTCHINSON M; MILTENBURGER C; BECKMANN K; DAHLKE F; KAPPOS L; POLMAN C; POZZILLI C; THE EUROPEAN STUDY GROUP ON INTERFERON BETA-1B IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS; MASSACESI L;
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/254559
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 59
social impact